Owing to its central role in preventing excitotoxicity and its presence in both CSF and plasma EVs during MS relapses, EAAT2 was selected for validation as biomarker of disease activity in RRMS and evaluation in SPMS patients. The gene discussed is SLC1A2; the disease is myeloid sarcoma.